登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 公司致力于医药、大健康和高科技产业投资，未来将打造医药创新、医疗器械和医药服务的大健康产业 集群和TMT方向的高科技产业集群，把握中国经济转型的机遇。公司愿景是"健康承载梦想，行动成就 未来"。 根据申万行业分类（2021），向日葵（维权）属于医药生物-化学制药-化学制剂。 2026年1月14日，公司收到中国证监会下发的《立案告知书》（编号：证监立案字01120260003号），因 公司涉嫌信息披露违法违规被立案调查。 立案后，公司股票的表现如下： 而在中国证券监督管理委员会的官网：发布了标题为《浙江证监局对向日葵重组预案涉嫌误导性陈述立 案调查》：2025年9月22日，浙江向日葵大健康科技股份有限公司（简称向日葵）披露重组预案。近 期，重组标的的实际产能和业务模式引发市场质疑，浙江证监局依法开展核查工作，发现重组预案涉嫌 误导性陈述。 初步判断：20 ...

（文章来源：证券日报） 证券日报网讯 1月14日，盟科药业发布公告称，公司通过国家高新技术企业重新认定，由全国高新技术 企业认定管理工作领导小组办公室核发，可连续三年按15%税率缴纳企业所得税，有助于提升核心竞争 力。 ...

Core Viewpoint - The stock of Hongbo Pharmaceutical (301230) has experienced significant trading volatility, with a cumulative price deviation exceeding 30% over two consecutive trading days and over 100% over five trading days [1] Group 1: Stock Performance - The company's stock price has shown a cumulative deviation of over 30% in closing prices for two consecutive trading days [1] - Over a span of five trading days, the cumulative deviation in closing prices has exceeded 100% [1] Group 2: Company Operations - The company reports that its operations are normal and there have been no significant changes [1] - The direct revenue from the DiOrion platform drug development services constitutes a small portion of the company's overall revenue and does not significantly impact the overall business performance [1]

Core Viewpoint - The company, Hongbo Pharmaceutical, announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of over 30% in closing prices over two consecutive trading days [1] Group 1: Company Operations - The company conducted a self-examination and confirmed that there are no undisclosed significant matters regarding its operations as of the announcement date [1] - The company's current operations are normal, and there have been no significant changes [1] Group 2: Revenue Impact - The direct revenue from the DiOrion platform's drug development services constitutes a small proportion of the company's overall revenue, thus not significantly impacting the overall business performance [1]

Core Viewpoint - The company, Hongbo Pharmaceutical, has experienced significant stock price fluctuations since January 8, 2026, with a cumulative increase surpassing most peers in the industry and significantly exceeding the growth of relevant indices such as the ChiNext Index, ChiNext 50, and Shenzhen Component Index [1] Group 1 - The company's stock price has shown a substantial increase, leading to a higher profit adjustment risk due to accumulated gains [1] - A self-examination was conducted by the company, and a letter was sent to the controlling shareholder and actual controller for verification, confirming no undisclosed significant matters related to the company as of the announcement date [1] - The company's operations are currently normal, with no significant changes reported [1] Group 2 - The direct revenue from the DiOrion platform's drug development services constitutes a small proportion of the company's overall operating income, indicating it does not significantly impact the overall business performance [1]

Core Viewpoint - The company, Aoxiang Pharmaceutical, is actively expanding its international business presence and aims to enhance its market penetration in regions such as Europe, America, Japan, and South Korea [2] Group 1 - The company exports its products to various countries and regions, including Europe, America, Japan, and South Korea [2] - Aoxiang Pharmaceutical plans to deepen its international business layout [2] - The company aims to further increase its international market penetration rate [2]

（文章来源：证券日报） 证券日报网讯 1月14日，东亚药业发布公告称，公司预计2025年度归属于上市公司股东的净利润为负 值，2025年度经营业绩将出现亏损。 ...

Core Viewpoint - Lianhuan Pharmaceutical (600513.SH) announced that its financial department has conducted preliminary calculations, predicting a negative net profit attributable to shareholders for the fiscal year 2025, indicating an expected operational loss for that year [1] Financial Performance - The company anticipates a net profit for 2025 to be negative, suggesting a decline in financial performance [1]

证券日报网讯 1月14日，宏源药业在互动平台回答投资者提问时表示，公司密切关注各产品市场变动情 况，并及时调整营销策略。公司境内、外具体营销情况请关注公司后续定期报告。 （文章来源：证券日报） ...

Group 1: Small Nucleic Acid Business - The company's small nucleic acid business primarily includes phosphoramidite monomers and GalNAc delivery systems, with the capability to provide modified monomer processes to meet diverse customer needs [2][3] - Pricing for small nucleic acid monomers varies based on customer requirements, including different segments, quantities, and stages [3] - The company began its small nucleic acid business layout in 2024, driven by overseas agency promotion and technical cooperation [3] Group 2: Supply Chain and Production Capacity - MNC suppliers generally do not change key material suppliers easily due to the need for global registration and product process validation [3] - The company's production capacity is expected to meet the demands of small nucleic acid business as fundraising projects gradually release capacity [3] Group 3: Stem Cell Projects - The company has made progress in its cell therapy projects, including the completion of GMP facility design, installation, and validation for heart and brain infarction projects [3] - Technical transfers for umbilical cord mesenchymal stem cells have been completed, establishing seed, master, and working cell banks, along with method development and validation for analysis [3] Group 4: Investor Relations Activity - The investor relations activity took place on January 14, 2026, from 10:30 to 11:30 in the company meeting room, involving various investment firms [2] - The activity did not involve the disclosure of any undisclosed significant information [3]